Inspection·November 2, 2024

F 0624 Prepare residents for a safe transfer or discharge from the nursing home. Level of Harm - Minimal harm or potential for actual harm **NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on record review, interview, and policy review the facility failed to ensure a safe and orderly discharge for Resident #3. The affected one resident (#3) of three residents reviewed for discharge planning. Residents Affected - Few Findings include: Review of the medical record for Resident #3 revealed an admission date of 08/10/24 and discharge date of 10/04/24. Diagnoses included type two diabetes, other chronic osteomyelitis, right ankle, and chronic kidney disease. Review of the comprehensive Minimum Data Set (MDS) assessment, dated 08/17/24, revealed Resident #3 had intact cognition. Review of the discharge care plan dated 10/04/24 revealed Resident #3's plan was to discharge home. Review of the physician order dated 08/22/24 revealed an order for tirzepatide (Mounjaro) 7.5 milligrams (mg) weekly for diabetes. Review of the Discharge summary dated [DATE] revealed Resident #3 was discharged with instructions provided and services set up. All medications were sent with the resident except Mounjaro 7.5 mg. Review of the Discharge Medication Receipt dated 10/04/24 revealed staff provided all medications except Mounjaro 7.5 mg. Interview on 11/02/24 at 9:30 A.M. with Resident #3 revealed the facility failed to supply the Mounjaro 7.5 mg injections when he discharged . Resident #3 stated he received an injection on 10/03/24 and then on 10/11/24 which was a day later than scheduled due to not having the medication. The pharmacy filled a prescription for Mounjaro 7.5 mg on 09/24/24 which included four injections. The pharmacy where he went for his medications upon discharge would not refill the medication after his discharge because the refill date was 10/24/24. After several calls to the pharmacy and insurance company, the pharmacy was able to provide the Mounjaro on 10/11/24. Interview on 11/02/24 at 10:15 A.M. with the Administrator and Director of Nursing revealed the nurse who discharged Resident #3 did not look in the refrigerator for any unused Mounjaro belonging to Resident #3 because he received an injection the day before he was discharged . The Administrator said the facility destroyed all medications left behind due to the facility policy. Documentation was provided and reviewed which confirmed Resident #3's Mounjaro was destroyed after his discharge from (continued on next page) Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation. LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE TITLE (X6) DATE FORM CMS-2567 (02/99) Previous Versions Obsolete Facility ID: If continuation sheet Page 1 of 2 Event ID: 366459 Printed: 05/15/2026 Form Approved OMB No. 0938-0391 Department of Health & Human Services Centers for Medicare & Medicaid Services STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION (X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: (X2) MULTIPLE CONSTRUCTION 366459 B. Wing A. Building (X3) DATE SURVEY COMPLETED 11/02/2024 NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE Brunswick Pointe Transitional Care 4355 Laurel Road Brunswick, OH 44212 For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency. (X4) ID PREFIX TAG SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)